Anzeige
Mehr »
Donnerstag, 15.05.2025 - Börsentäglich über 12.000 News
Der Schlüssel zum Erfolg: Könnte sich hier eine 1.000?%-Chance verbergen!?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: 896047 | ISIN: US09058V1035 | Ticker-Symbol: BO1
Tradegate
14.05.25 | 18:53
8,798 Euro
+0,09 % +0,008
1-Jahres-Chart
BIOCRYST PHARMACEUTICALS INC Chart 1 Jahr
5-Tage-Chart
BIOCRYST PHARMACEUTICALS INC 5-Tage-Chart
RealtimeGeldBriefZeit
8,6568,87407:37
8,6568,87407:37

Aktuelle News zur BIOCRYST PHARMACEUTICALS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
BIOCRYST PHARMACEUTICALS Aktie jetzt für 0€ handeln
MiBIOCRYST PHARMACEUTICALS INC - 8-K, Current Report3
05.05.BioCryst Pharmaceuticals Soars 23% In One Session - Here's Why It Surprised Investors18
05.05.BioCryst stock target to $14 on Orladeyo sales, maintains Buy6
05.05.BioCryst targets $1B in global ORLADEYO revenue by 2029 amid 33-37% projected growth this year4
05.05.BioCryst stock jumps on raised guidance, strong Q1 report3
05.05.Napco Security Technologies Posts Better-Than-Expected Results, Joins Skechers, BioCryst Pharmaceuticals And Other Big Stocks Moving Higher On Monday7
05.05.BioCryst Hikes on Q1 Figures2
05.05.Biocryst Pharma Posts Profit In Q1; Sees Profit In FY25, Lifts ORLADEYO Revenue View; Stock Climbs7
05.05.BioCryst Q1 2025 slides: ORLADEYO sales surge, guidance raised4
05.05.Biocryst Pharmaceuticals Inc Q1 Earnings Summary3
05.05.BioCryst Pharmaceuticals beats top-line and bottom-line estimates; updates FY25 outlook6
05.05.BioCryst Pharmaceuticals, Inc.: BioCryst Reports First Quarter 2025 Financial Results and Provides Business Update203-Q1 2025 ORLADEYO net revenue of $134.2 million (+51 percent y-o-y)- -Full year 2025 ORLADEYO revenue guidance increased to $580 million to $600 million- -Company now expects to be profitable for...
► Artikel lesen
02.05.BioCryst Pharmaceuticals, Inc.: BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)106RESEARCH TRIANGLE PARK, N.C., May 02, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst's board of directors granted...
► Artikel lesen
01.05.BioCryst beruft J.P. Morgan-Führungskraft in den Vorstand4
01.05.BIOCRYST PHARMACEUTICALS INC - 8-K, Current Report1
01.05.BioCryst Pharmaceuticals, Inc.: BioCryst Appoints Steve Frank to Board of Directors4
29.04.Cantor Fitzgerald sets BioCryst stock at Overweight, $20 target1
21.04.BioCryst Pharmaceuticals, Inc.: BioCryst to Report First Quarter 2025 Financial Results on May 53
10.04.BioCryst Pharmaceuticals appoints Jon P. Stonehouse as interim CFO4
10.04.BIOCRYST PHARMACEUTICALS INC - 8-K, Current Report3
Seite:  Weiter >>
64 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1